| Title: |
Clinical Course of Candidate Renal Transplant Recipients Diagnosed With Prostate Cancer During Pre-transplant Screening Test. |
| Authors: |
YUKI KOBARI, JUNPEI IIZUKA, CHIKA NAGAHISA, RYO MINODA, KOHEI UNAGAMI, KAZUHIKO YOSHIDA, TOSHIHITO HIRAI, TOMOKAZU SHIMIZU, HIDEKI ISHIDA, TOSHIO TAKAGI |
| Source: |
In Vivo; Jan/Feb2024, Vol. 38 Issue 1, p496-499, 4p |
| Subject Terms: |
PROSTATE cancer, KIDNEY transplantation, PROSTATE-specific antigen, CANCER radiotherapy, CANCER hormone therapy |
| Abstract: |
Background/Aim: Occasionally, candidate renal transplant recipients (RTRs) are incidentally diagnosed with prostate cancer (PCa) during pre-transplant screening examinations; however, their clinical course remains unclear. This study aimed to clarify the clinical course of RTR diagnosed with PCa during pre-transplant screening tests. Patients and Methods: Between April 2008 and April 2022, 15 candidates for RTRs were newly diagnosed with PCa during the screening test. We analyzed the patients' treatment choices, initial treatment results, waiting duration for renal transplantation, and whether they finally underwent transplantation. Results: The median patient age was 64 years (range=52-75 years). The median prostate-specific antigen level was 6.9 ng/ml (5.2-56.9 ng/ml). According to D'Amico risk stratification, one, 10, and four patients were at low, intermediate, and high risk, respectively. As for treatment choice, 13 patients chose surgery. Moreover, intensitymodulated radiotherapy and hormone therapy were chosen by one patient each. Of these, seven patients underwent transplantation, with a median waiting time from initial treatment to transplantation of 20.3 months (9.2-40.0 months). One patient discontinued transplantation owing to poor cancer control, four patients had donor issues (change in mind, aging, or disease), and one patient waited because pathological findings revealed locally invasive cancer. Conclusion: PCa diagnosis in candidate RTRs during the pre-transplant screening test impacts the candidate's clinical course. [ABSTRACT FROM AUTHOR] |
|
Copyright of In Vivo is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
